{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968515",
  "id": "02968515",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250711",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250711/pdf/06lq1p1mfmmkvx.pdf",
  "summary": "- **Board Appointment**: Dr Thomas Duthy appointed as Non-Executive Director (effective 11 July 2025), bringing healthcare/life sciences capital markets and M&A expertise (e.g., key role in Sirtex Medical's $1.9bn acquisition).  \n- **Director Share Issuance**: Duthy to receive shares at $1.50 (25% premium to recent capital raise price) in lieu of first-year director fees, subject to shareholder approval; shares escrowed for 12 months.  \n- **Director Resignation**: Dr Gabriel Liberatore resigns from the Board (effective 11 July 2025).  \n\n*No material trading or capital markets impacts identified beyond board composition and alignment incentive.*",
  "usage": {
    "prompt_tokens": 1599,
    "completion_tokens": 149,
    "total_tokens": 1748,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T23:56:05.969357"
}